Redhill Biopharma Ltd
RDHL
Company Profile
Business description
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Contact
21 Ha’arba’a Street
Tel Aviv6473921
ISRT: +972 35413131
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
35
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
We think Microsoft stock is moderately undervalued.
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,230.10 | 23.40 | 0.25% |
| CAC 40 | 8,157.29 | 43.59 | -0.53% |
| DAX 40 | 24,118.89 | 5.32 | -0.02% |
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% |
| FTSE 100 | 9,760.06 | 3.92 | 0.04% |
| HKSE | 26,282.69 | 63.45 | -0.24% |
| NASDAQ | 23,581.14 | 377.33 | -1.57% |
| Nikkei 225 | 52,199.36 | 873.75 | 1.70% |
| NZX 50 Index | 13,529.28 | 69.99 | 0.52% |
| S&P 500 | 6,822.34 | 68.25 | -0.99% |
| S&P/ASX 200 | 8,933.20 | 20.00 | 0.22% |
| SSE Composite Index | 3,986.86 | 0.04 | -0.00% |